Biogen MS trial data robust; shares jump | Reuters
"BG-12 may be a valuable treatment option for MS patients, combining strong efficacy, a favorable safety profile and oral administration," said Dr. Ralf Gold, a trial investigator and professor at St. Josef-Hospital/Ruhr-University in Bochum, Germany. "Preclinical research has shown that BG-12 has anti-inflammatory and neuroprotective effects."
No comments:
Post a Comment